A bloody battle over ESAs: CMS, despite evidence from recent trials, decides to keep current payment policies for the anemia drugs intact-for now

Dialysis and Transplantation

Volumn 40, Issue 4, 2011, Pages 142-143

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR RISK; DRUG FATALITY; DRUG LEGISLATION; DRUG SAFETY; HEART INFARCTION; HUMAN; MEDICARE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; SHORT SURVEY; STROKE;

EID: 79954552618     PISSN: 00902934     EISSN: 19326920     Source Type: Journal    
DOI: 10.1002/dat.20559     Document Type: Short Survey

References (5)

1. Heavey S,. Not enough data on anemia drugs. MedscapeMedical News. Updated January 20, 2011. Accessed March 17, 2011.
2. CMS set to open national coverage analysis on ESAs. Alabama Cancer Congress website. Updated April 21, 2010. Accessed March 17, 2011.
3. NationalKidneyFoundationadvisoryonKDOQI clinical practice guidelines. National Kidney Foundation. Accessed March 17, 2011.
4. Singh AK,. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol. 2010; 21: 1-13.
5. Score sheet on the impact of ESA use on renal transplant graft survival. Centers for Medicare and Medicaid Services. Updated January 19, 2011. Accessed March 17, 2011.